Alembic Pharmaceuticals Reports 12% Profit Increase and 25% Revenue Growth in Q1 FY27
Alembic Pharmaceuticals reported a 12.1% rise in consolidated net profit to around Rs 173 crore for Q1 FY27, compared to Rs 154 crore in the same quarter last year. Revenue increased 25.66% to approximately Rs 2,150 crore, driven by growth in the US formulation, India branded, and API businesses. Total expenses also rose to Rs 1,943 crore. The company attributed the performance to volume growth, new product launches, and market execution, with auditors issuing an unmodified conclusion on the results.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (61/100). Lens Score 37/100.
Outlets measured: businessstandard, businessstandard, news18, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 4 Aug, 08:55 am. Other outlets followed.